EDP-323
Small molecule
Evidence outlook · lead readout
NCT06170242 · Respiratory Syncytial Virus Infection
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06170242: In this randomized, double-blind, placebo-controlled Phase 2a challenge study, healthy volunteers were deliberately infected with RSV and then treated with EDP-323 or placebo. Both EDP-323 doses significantly reduced the amount of virus detected in nasal samples compared with placebo, but the trial measured viral load rather than a direct clinical symptom or disease outcome.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06847464 NCT06847464 · Respiratory Syncytial Virus Infection Registry: NCT06847464 | 1 | Cmax of EDP-323 with and without coadministration with Itraconazole (Day 1 through Day 19); AUC of EDP-323 with and without coadministration with Itraconazole (Day 1 through Day 19); Cmax of EDP-323 with and without coadministration with Carbamazepine (Day 1 through Day 28); AUC of EDP-323 with and without coadministration with Carbamazepine (Day 1 through Day 28); Cmax of EDP-323 with and without coadministration with Quinidine (Day 1 through Day 13); AUC of EDP-323 with and without coadministration with Quinidine (Day 1 through Day 13); Cmax of EDP-323 with and without coadministration with fluconazole (Day 1 through Day 19); AUC of EDP-323 with and without coadministration with fluconazole (Day 1 through Day 19) 2025-05-24 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT06170242 NCT06170242 · Respiratory Syncytial Virus Infection In this randomized, double-blind, placebo-controlled Phase 2a challenge study, healthy volunteers were deliberately infected with RSV and then treated with EDP-323 or placebo. Both EDP-323 doses significantly reduced the amount of virus detected in nasal samples compared with placebo, but the trial measured viral load rather than a direct clinical symptom or disease outcome. Registry: NCT06170242 | 2 | Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12) 2024-06-17 | Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Respiratory Syncytial Virus Infection: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| EDP-323: this drug | Phase 2 | Small molecule | RSV L protein | Partial signal | NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743) | |
| Clesrovimab (Enflonsia) | Approved | Monoclonal antibody | RSV F protein | not yet graded | No reviewed efficacy summary in this indication | |
| mRESVIA | Approved | Vaccine | RSV pre-F protein | Partial signal | NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses). | |
| Zelicapavir | Phase 2 | Small molecule | RSV N protein (nucleoprotein) | Weak signal | NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants | |
| GSK5893818 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0256 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0291 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0340 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0341 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.